Targeting the PI3K/AKT/mTOR pathway presents a promising therapeutic approach for keloid treatment, given its central role in controlling fibroblast proliferation, migration, survival, and myofibroblast differentiation, processes fundamental to keloid pathogenesis (Kim and Kim, 2024). The gene discussed is MTOR; the disease is keloid.